-+ 0.00%
-+ 0.00%
-+ 0.00%

Whitehawk says Phase 1 trial for HWK-016 ADC in ovarian, endometrial cancers ongoing

PUBT·04/19/2026 22:00:34
Listen to the news
Whitehawk says Phase 1 trial for HWK-016 ADC in ovarian, endometrial cancers ongoing
  • Whitehawk Therapeutics announced new preclinical data on its next-generation antibody-drug conjugate portfolio at AACR 2026, with results presented at the meeting.
  • Data showed tumor shrinkage across multiple models with a safety profile described as favorable, supporting a differentiated risk-benefit profile for its platform.
  • Ongoing Phase 1 trials for HWK-007 and HWK-016 remained active, with the update framed as supportive of continued clinical development.
  • Plans call for an IND filing for HWK-206 in mid-2026, positioning a Phase 1 start in Q3 2026 as the next value-driving catalyst.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604191800PR_NEWS_USPR_____LA37368) on April 19, 2026, and is solely responsible for the information contained therein.